|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chaturvedi S and Garcia JA: Novel agents
in the management of castration resistant prostate cancer. J
Carcinog. 13:52014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ni J, Cozzi PJ, Hao JL, Beretov J, Chang
L, Duan W, Shigdar S, Delprado WJ, Graham PH, Bucci J, et al: CD44
variant 6 is associated with prostate cancer metastasis and
chemo-/radioresistance. Prostate. 74:602–617. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nakano K, Komatsu K, Kubo T, Natsui S,
Nukui A, Kurokawa S, Kobayashi M and Morita T: External validation
of risk classification in patients with docetaxel-treated
castration-resistant prostate cancer. BMC Urol. 14:312014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cohen JH, Kristal AR and Stanford JL:
Fruit and vegetable intakes and prostate cancer risk. J Natl Cancer
Inst. 92:61–68. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang SM, Hunter DJ, Rosner BA,
Giovannucci EL, Colditz GA, Speizer FE and Willett WC: Intakes of
fruits, vegetables, and related nutrients and the risk of
non-Hodgkin's lymphoma among women. Cancer Epidemiol Biomarkers
Prev. 9:477–485. 2000.PubMed/NCBI
|
|
7
|
Ambrosone CB, McCann SE, Freudenheim JL,
Marshall JR, Zhang Y and Shields PG: Breast cancer risk in
premenopausal women is inversely associated with consumption of
broccoli, a source of isothiocyanates, but is not modified by GST
genotype. J Nutr. 134:1134–1138. 2004.PubMed/NCBI
|
|
8
|
Dinkova-Kostova AT and Kostov RV:
glucosinolates and isothiocyanates in health and disease. Trends
Mol Med. 18:337–347. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Choi S and Singh SV: Bax and Bak are
required for apoptosis induction by sulforaphane, a cruciferous
vegetable-derived cancer chemopreventive agent. Cancer Res.
65:2035–2043. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Talalay P and Fahey JW: Phytochemicals
from cruciferous plants protect against cancer by modulating
carcinogen metabolism. J Nutr. 131(Suppl): 3027S–3033S.
2001.PubMed/NCBI
|
|
11
|
Conaway CC, Yang YM and Chung FL:
Isothiocyanates as cancer chemopreventive agents: Their biological
activities and metabolism in rodents and humans. Curr Drug Metab.
3:233–255. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lenzi M, Fimognari C and Hrelia P:
Sulforaphane as a promising molecule for fighting cancer. Cancer
Treat Res. 159:207–223. 2014. View Article : Google Scholar
|
|
13
|
Cheung KL and Kong AN: Molecular targets
of dietary phenethyl isothiocyanate and sulforaphane for cancer
chemoprevention. AAPS J. 12:87–97. 2010. View Article : Google Scholar :
|
|
14
|
Clarke JD, Dashwood RH and Ho E:
Multi-targeted prevention of cancer by sulforaphane. Cancer Lett.
269:291–304. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hecht SS: Inhibition of carcinogenesis by
isothiocyanates. Drug Metab Rev. 32:395–411. 2000. View Article : Google Scholar
|
|
16
|
Li C, Zhou Y, Peng X, Du L, Tian H, Yang
G, Niu J and Wu W: Sulforaphane inhibits invasion via activating
ERK1/2 signaling in human glioblastoma U87MG and U373MG cells. PLoS
One. 9:e905202014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Deschênes-Simard X, Kottakis F, Meloche S
and Ferbeyre G: ERKs in cancer: Friends or foes? Cancer Res.
74:412–419. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhou Y, Hu HY, Meng W, Jiang L, Zhang X,
Sha JJ, Lu Z and Yao Y: MEK inhibitor effective against
proliferation in breast cancer cell. Tumour Biol. 35:9269–9279.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Judd NP, Winkler AE, Murillo-Sauca O,
Brotman JJ, Law JH, Lewis JS Jr, Dunn GP, Bui JD, Sunwoo JB and
Uppaluri R: ERK1/2 regulation of CD44 modulates oral cancer
aggressiveness. Cancer Res. 72:365–374. 2012. View Article : Google Scholar :
|
|
20
|
Lau MT, So WK and Leung PC: Fibroblast
growth factor 2 induces E-cadherin down-regulation via
PI3K/akt/mToR and MAPK/ERK signaling in ovarian cancer cells. PLoS
One. 8:e590832013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Burotto M, Chiou VL, Lee JM and Kohn EC:
The MaPK pathway across different malignancies: A new perspective.
Cancer. 120:3446–3456. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Marshall CJ: Specificity of receptor
tyrosine kinase signaling: Transient versus sustained extracellular
signal-regulated kinase activation. Cell. 80:179–185. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu W, Ginsburg E, Vonderhaar BK and Walker
AM: S179D prolactin increases vitamin D receptor and p21 through
up-regulation of short 1b prolactin receptor in human prostate
cancer cells. Cancer Res. 65:7509–7515. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu Z, Yu X and Shaikh ZA: Rapid
activation of ERK1/2 and AKT in human breast cancer cells by
cadmium. Toxicol Appl Pharmacol. 228:286–294. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang TY, Chang GC, Chen KC, Hung HW, Hsu
KH, Sheu GT and Hsu SL: Sustained activation of ERK and
Cdk2/cyclin-A signaling pathway by pemetrexed leading to S-phase
arrest and apoptosis in human non-small cell lung cancer A549
cells. Eur J Pharmacol. 663:17–26. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li Z, Du L, Li C and Wu W: Human chorionic
gonadotropin β induces cell motility via ERK1/2 and MMP-2
activation in human glioblastoma U87MG cells. J Neurooncol.
111:237–244. 2013. View Article : Google Scholar
|
|
27
|
Li Z, Li C, Du L, Zhou Y and Wu W: Human
chorionic gonadotropin β induces migration and invasion via
activating ERK1/2 and MMP-2 in human prostate cancer DU145 cells.
PLoS One. 8:e545922013. View Article : Google Scholar
|
|
28
|
Wheelock MJ and Johnson KR: Cadherins as
modulators of cellular phenotype. Annu Rev Cell Dev Biol.
19:207–235. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cavallaro U and Christofori G: Cell
adhesion and signalling by cadherins and Ig-CaMs in cancer. Nat Rev
Cancer. 4:118–132. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li Q and Mattingly RR: Restoration of
E-cadherin cell-cell junctions requires both expression of
E-cadherin and suppression of ERK MAP kinase activation in
Ras-transformed breast epithelial cells. Neoplasia. 10:1444–1458.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bae GY, Choi SJ, Lee JS, Jo J, Lee J, Kim
J and Cha HJ: Loss of E-cadherin activates EGFR-MEK/ERK signaling,
which promotes invasion via the ZEB1/MMP2 axis in non-small cell
lung cancer. Oncotarget. 4:2512–2522. 2013.PubMed/NCBI
|
|
33
|
Nagano O, Okazaki S and Saya H: Redox
regulation in stem-like cancer cells by CD44 variant isoforms.
Oncogene. 32:5191–5198. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Khan SA, Cook AC, Kappil M, Günthert U,
Chambers AF, Tuck AB and Denhardt DT: Enhanced cell surface CD44
variant (v6, v9) expression by osteopontin in breast cancer
epithelial cells facilitates tumor cell migration: Novel
post-transcriptional, post-translational regulation. Clin Exp
Metastasis. 22:663–673. 2005. View Article : Google Scholar
|
|
35
|
Akisik E, Bavbek S and Dalay N: CD44
variant exons in leukemia and lymphoma. Pathol Oncol Res. 8:36–40.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lee JL, Wang MJ, Sudhir PR, Chen GD, Chi
CW and Chen JY: Osteopontin promotes integrin activation through
outside-in and inside-out mechanisms: OPN-CD44v interaction
enhances survival in gastrointestinal cancer cells. Cancer Res.
67:2089–2097. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mulder JW, Wielenga VJ, Polak MM, van den
Berg FM, Adolf GR, Herrlich P, Pals ST and Offerhaus GJ: Expression
of mutant p53 protein and CD44 variant proteins in colorectal
tumorigenesis. Gut. 36:76–80. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jones JL and Walker RA: Control of matrix
metalloproteinase activity in cancer. J Pathol. 183:377–379. 1997.
View Article : Google Scholar
|
|
39
|
Orlichenko LS and Radisky DC: Matrix
metalloproteinases stimulate epithelial-mesenchymal transition
during tumor development. Clin Exp Metastasis. 25:593–600. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bérubé M, Deschambeault A, Boucher M,
Germain L, Petitclerc E and Guérin SL: MMP-2 expression in uveal
melanoma: Differential activation status dictated by the cellular
environment. Mol vis. 11:1101–1111. 2005.PubMed/NCBI
|
|
41
|
Sato T, Sakai T, Noguchi Y, Takita M,
Hirakawa S and Ito A: Tumor-stromal cell contact promotes invasion
of human uterine cervical carcinoma cells by augmenting the
expression and activation of stromal matrix metalloproteinases.
Gynecol Oncol. 92:47–56. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Di Nezza LA, Misajon A, Zhang J, Jobling
T, Quinn MA, Ostör AG, Nie G, Lopata A and Salamonsen LA: Presence
of active gelatinases in endometrial carcinoma and correlation of
matrix metalloproteinase expression with increasing tumor grade and
invasion. Cancer. 94:1466–1475. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gupta P, Kim B, Kim SH and Srivastava SK:
Molecular targets of isothiocyanates in cancer: Recent advances.
Mol Nutr Food Res. 58:1685–1707. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Shan Y, Zhang L, Bao Y, Li B, He C, Gao M,
Feng X, Xu W, Zhang X and Wang S: Epithelial-mesenchymal
transition, a novel target of sulforaphane via COX-2/MMP2, 9/Snail,
ZEB1 and miR-200c/ZEB1 pathways in human bladder cancer cells. J
Nutr Biochem. 24:1062–1069. 2013. View Article : Google Scholar
|
|
45
|
Hahm ER, Chandra-Kuntal K, Desai D, Amin S
and Singh SV: Notch activation is dispensable for D,
L-sulforaphane-mediated inhibition of human prostate cancer cell
migration. PLoS One. 7:e449572012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Jo C, Kim S, Cho SJ, Choi KJ, Yun SM, Koh
YH, Johnson GV and Park SI: Sulforaphane induces autophagy through
ERK activation in neuronal cells. FEBS Lett. 588:3081–3088. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Shen KH, Liao AC, Hung JH, Lee WJ, Hu KC,
Lin PT, Liao RF and Chen PS: α-Solanine inhibits invasion of human
prostate cancer cell by suppressing epithelial-mesenchymal
transition and MMPs expression. Molecules. 19:11896–11914. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wu W and Walker AM: Human chorionic
gonadotropin beta (HCGbeta) down-regulates E-cadherin and promotes
human prostate carcinoma cell migration and invasion. Cancer.
106:68–78. 2006. View Article : Google Scholar
|
|
49
|
Brown RL, Reinke LM, Damerow MS, Perez D,
Chodosh LA, Yang J and Cheng C: CD44 splice isoform switching in
human and mouse epithelium is essential for epithelial-mesenchymal
transition and breast cancer progression. J Clin Invest.
121:1064–1074. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wu G, Zhou Y, Li T, Guo J and Zhou Z:
Immunohistochemical levels of matrix metalloproteinase-2 and CD44
variant 6 protein in the diagnosis and lateral cervical lymph node
metastasis of papillary thyroid carcinoma. J Int Med Res.
41:816–824. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yu Q and Stamenkovic I: localization of
matrix metal-loproteinase 9 to the cell surface provides a
mechanism for CD44-mediated tumor invasion. Genes Dev. 13:35–48.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Chen Y, Zheng L, Liu J, Zhou Z, Cao X, Lv
X and Chen F: Shikonin inhibits prostate cancer cells metastasis by
reducing matrix metalloproteinase-2/-9 expression via AKT/mTOR and
RoS/ERK1/2 pathways. Int Immunopharmacol. 21:447–455. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wang Y, Li M, Xu Y, He N, Leng L and Li Z:
Tumor necrosis factor-α regulates matrix metalloproteinase-2
expression and cell migration via ERK pathway in rat glomerular
mesangial cells. Cell Biol Int. 38:1060–1068. 2014.PubMed/NCBI
|
